WILL GLP-1 GUMMIES AND GENERICS CHANGE? EVERYTHING? [plenty diet pills]

WILL GLP-1 GUMMIES AND GENERICS CHANGE? EVERYTHING? [plenty diet pills]

| 1h 28m 28s | Video has closed captioning.

Big Pharma Moves and GLP-1 Market Shifts: What's New in 2025? In this week's episode of the Downsized News, hosts Laraine and Christopher Durham discuss major updates on GLP-1 medications and their impact on various sectors. They explore how GLP-1s are changing grocery spending and highlight the introduction of the first compounded semaglutide gummy. The episode covers legal battles, including Eli Lilly's intervention in the tripeptide case and the FDA's handling of compounded medications. They also look into the approval of a generic version of Victoza, shifts in the obesity drug market, and the growing competition among pharmaceutical giants like Eli Lilly and Novo Nordisk. Finally, they discuss the potential impact of Robert F. Kennedy Jr.'s nomination as head of health and human services on the vaccine industry. We use Mochi Health: Use Laraine’s code for $40 off: QIYGO8. DOWNSIZED WEBSITE: JOIN CLUB DOWNSIZED: DOWNSIZED GLP-1 COMPANION PRODUCT STORE: 00:00 Introduction and Overview 00:18 Meet the Hosts 01:40 Legal Battles and Market Dynamics 04:00 Impact on Grocery Spending 06:45 Generic Liraglutide Approval 08:59 Compounded Semaglutide Gummy 11:39 Eli Lilly's Obesity Market Moves 16:02 Pharmaceutical Market Projections 19:13 Conclusion and Wrap-Up